ArticleInternational journal of clinical and experimental pathology2018
Lentinan up-regulates microRNA-340 to promote apoptosis and autophagy of human osteosarcoma cells.
Article in International journal of clinical and experimental pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 10 citations in OpenAlex.
- Induction of Autophagy and Its Role in Peripheral Nerve Regeneration after Peripheral Nerve Injury.International journal of molecular sciences · 2023Review
- The chemistry and efficacy benefits of polysaccharides fromFrontiers in pharmacology · 2022Review
- Challenges and Perspectives of Standard Therapy and Drug Development in High-Grade Gliomas.Molecules (Basel, Switzerland) · 2021Review
- Anti-neoplastic Potential of Flavonoids and Polysaccharide Phytochemicals in Glioblastoma.Molecules (Basel, Switzerland) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOsteosarcoma (OS) is a common tumor of bone, and the high incidence and poor prognosis of OS call for novel therapeutic strategies. We aimed to explore the functional role of lentinan (LNT) in human OS MG63 cells as well as the underlying mechanisms.
methodsCell viability of MG63 cells under LNT stimulation was measured by CCK-8 assay to explore the adequate concentration of LNT. Cell proliferation, apoptosis and expression of microRNA (miR)-340 in MG63 cells after LNT treatments were assayed by BrdU incorporation assay, flow cytometry assay and quantitative reverse transcription PCR, respectively. Expression of proteins associated with cell cycle, apoptosis, and autophagy were determined by western blot analysis. Subsequently, whether LNT affected MG63 cells through miR-340 as well as the related signaling pathway was explored.
resultsCell viability was reduced by 5-100 mg/mL of LNT. Percentage of BrdU-positive cells was reduced while that of apoptotic cells was enhanced by LNT treatment. LNT decreased cyclin D1 level but increased levels of active caspase-3 and caspase-9. After treatment, LNT enhanced LC3B-II/LC3B-I and Beclin-1 levels but reduced the p62 level. The miR-340 level was up-regulated by LNT, and further experiments showed LNT promoted apoptosis and autophagy through up-regulating miR-340. Moreover, LNT reduced the phosphorylated levels of MAPK and ERK through up-regulating miR-340.
conclusionLNT reduced proliferation and induced apoptosis and autophagy by up-regulating miR-340 in MG63 cells, along with inhibition of the MAPK/ERK pathway.
Indexed as
Identifiers
31949775PMC6962797W3026396671What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.